Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis.

ABSTRACT:

Background

Tumor mutation burden (TMB) remains a promising but ambiguous predictive biomarker for the efficacy of immune checkpoint inhibitors (ICIs). We investigated the predictive value of TMB in patients with advanced non-small cell lung cancer (NSCLC) treated by ICI-containing therapies under strictly matched clinical settings.

Methods

PubMed, Embase, Cochrane Central, ClinicalTrials.gov, and bioRxiv databases were searched till October 16, 2021. All randomized controlled trials (RCTs) that compared patients with high TMB (TMB-H) and low TMB (TMB-L) and provided hazard ratio (HR) and corresponding 95% confidence interval (CI) in advanced NSCLC patients receiving ICIs were included, and mirror-based meta-analysis was performed (Part1). Bayesian network meta-analysi

SUBMITTER: Zhao J 

PROVIDER: S-EPMC11256607 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature